1. Introduction {#sec1}
===============

The causative factors of neurodegenerative diseases such as Parkinson\'s disease (PD) remain unknown, although the involvement of environmental and/or endogenous neurotoxins is being increasingly considered \[[@B1]--[@B3]\]. Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a contaminant found in "synthetic heroin," produces neurotoxicity in humans, and this neurotoxin is commonly used to generate experimental parkinsonism in animal models \[[@B4]--[@B7]\]. MPTP crosses the blood-brain barrier and is bioactivated enzymatically to give 1-methyl-4-phenylpyridinium (MPP^+^) \[[@B1], [@B8], [@B9]\], which is selectively uptaken into dopaminergic cells via dopamine-activated transporter (DAT) and produces inhibition of mitochondrial complex I, energy depletion, and cell death \[[@B8]\] ([Figure 1](#fig1){ref-type="fig"}). Besides its use in experimental models of neurotoxicity, the toxic outcome caused by MPTP is a matter of investigation due to the differences in response among experimental models \[[@B10], [@B11]\]. This might result from a change in the balance between the rate of metabolism to toxic products (MPP^+^ and MPDP^+^) (activation) and the rate of detoxification (inactivation) \[[@B12]--[@B16]\]. MPTP is metabolized by enzymes such as cytochrome P450, and this could affect the outcome of this neurotoxin \[[@B12], [@B14], [@B17]--[@B19]\].

Humans are not usually exposed to MPTP but are exposed to some structural analogs such as the *β*-carboline alkaloids \[[@B20]--[@B22]\]. *β*-Carbolines appear in foods and are absorbed into the human body and brain, where they may exert psychopharmacological and toxic effects \[[@B23]--[@B28]\]. These compounds might follow a toxicological pattern similar to that of MPTP ([Figure 1](#fig1){ref-type="fig"}). Firstly, these alkaloids could be bioactivated to *N*-methyl derivatives and then oxidized (aromatized) to pyridinium-like *β*-carbolinium species \[[@B15], [@B20], [@B21], [@B29]\]. *β*-Carbolinium (*β*C^+^) species share several functional and toxicological properties with 1-methyl-4-phenylpyridinium (MPP^+^), which is the metabolite involved in MPTP neurotoxicity \[[@B30]--[@B32]\], and were postulated as potential slow-acting neurotoxins \[[@B33], [@B34]\]. Remarkably, *N*-methyl-*β*-carbolinium species such as *N*-methylnorharmanium (2-Me-*β*C^+^) and 2,9-dimethylnorharmanium (2,9-diMe-*β*C^+^) have been detected in postmortem human brains \[[@B34]--[@B36]\] and found in higher proportion in cerebrospinal fluid of patients with neurodegenerative diseases (PD) \[[@B35]\].

The toxicological outcome of MPTP and *β*-carbolines will depend on the metabolic profile produced by key enzymes leading to the activation/inactivation of these protoxins \[[@B21]\]. Therefore, studying the activation/inactivation (biotransformation) of MPTP and its naturally occurring analogs by metabolic enzymes is a matter of current interest in order to explain the toxicological features of these substances. It could lead to the identification of the enzyme responsible for activation and inactivation as well as the metabolites produced, and it may also suggest interindividual differences. In this regard, the purpose of this research was to study in a comparative way the metabolic profile generated from MPTP and its naturally occurring analog 2-methyltetrahydro-*β*-carboline by three metabolic enzymes: monoamine oxidase (MAO), heme peroxidase, and cytochrome P450 (2D6). Monoamine oxidase (MAO) is a flavoenzyme located at the outer membranes of mitochondria in the human brain and peripheral tissues that catalyzes the oxidative deamination of neurotransmitters and xenobiotic amines. MAO appears as two isozymes, MAO-A and B, and plays an important role in the central nervous system and peripheral organs \[[@B37]\]. MAO-A is involved in psychiatric conditions and depression and MAO-B is implicated in neurodegenerative diseases \[[@B37]--[@B41]\]. The cytochrome P450 enzymes are mixed-function oxidases involved in the metabolism of drugs and xenobiotics. In particular, the cytochrome P450 2D6 is present in the liver and extrahepatic tissues and participates in the metabolism and toxicity of many drugs with a basic nitrogen. This cytochrome presents strong polymorphism, characterized by poor, intermediate, extensive, and ultrarapid metabolizers, and it is currently being considered in relation to neurodegenerative diseases \[[@B17], [@B42]--[@B46]\]. Heme peroxidases participate in the oxidation of endogenous substrates, drugs, and xenobiotics \[[@B47]\]. Mammalian peroxidases such as myeloperoxidase (MPO), eosinophil peroxidase (EPO), and lactoperoxidase (LPO) are found in neutrophils, eosinophils, and secretory cells of the exocrine glands and participate in antimicrobial and anti-inflammatory processes. MPO occurs in activated microglia at sites of degenerative diseases \[[@B48]--[@B50]\]. Peroxidases in the substantia nigra may produce toxic substances and might be involved in PD and neurodegeneration \[[@B51], [@B52]\].

2. Material and Methods {#sec2}
=======================

2.1. Chemicals and Enzymes {#sec2.1}
--------------------------

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) hydrochloride (caution: MPTP is a neurotoxin and should be handled with appropriate precautions), 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP^+^) perchlorate, 1-methyl-4-phenylpyridinium (MPP^+^) iodide, 4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (PTP), and NADPH were from Sigma-Aldrich (St. Louis, MO, USA). 2-Methyl-1,2,3,4-tetrahydro-*β*-carboline hydrochloride (2-Me-TH*β*C), 2-methyl-3,4-dihydro-*β*-carbolinium chloride (2-Me-3,4-DH*β*C^+^), 2-methyl-*β*-carbolinium iodide (2-Me-*β*C^+^), and 4-(4′-hydroxyphenyl)-1-methyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP-OH) were obtained previously \[[@B14]--[@B16]\]. Human monoamine oxidases (MAO-A and -B) were obtained from BD Gentest Co. (Woburn, MA, USA). Microsomes containing recombinant human cytochrome P450 2D6\*1+cytochrome P450 oxidoreductase produced from baculovirus infected-insect cells were obtained from BD Gentest Co. (Woburn, MA, USA). Bovine lactoperoxidase (LPO) and human myeloperoxidase (MPO) were obtained from Sigma and Calbiochem (Merck), respectively, and the concentration in the assays is determined using the extinction coefficients of Soret bands \[[@B53]\].

2.2. Enzyme Biotransformation and Metabolic Profile {#sec2.2}
---------------------------------------------------

### 2.2.1. MAO Enzymes {#sec2.2.1}

0.2 mL reaction mixtures in 75 mM buffer phosphate (pH 7.4) containing human MAO-A or -B (0.01--0.2 mg/mL protein) and MPTP (50, 250 *μ*M) or 2-methyl-1,2,3,4-tetrahydro-*β*-carboline (50, 250 *μ*M) were incubated (37°C, 40 min); the reaction was stopped by the addition of 2 N NaOH (75 *μ*L) and 70% perchloric acid (25 *μ*L) subsequently centrifuged (9000 rpm, 5°C), and 20 *μ*L of the supernatant injected into the HPLC. The metabolic profile was analyzed by HPLC-DAD, and the metabolites identified by mass spectrometry (ESI). Incubations were performed at least in duplicate.

### 2.2.2. Cytochrome P450 2D6 {#sec2.2.2}

0.2 mL reaction mixtures in 75 mM phosphate buffer (pH 7.4) containing human cytochrome P450 2D6 (7 pmol P450) and MPTP (50, 250 *μ*M) or 2-methyl-1,2,3,4-tetrahydro-*β*-carboline (50, 250 *μ*M), and NADPH (1 mM) were incubated at 37°C, 25 min. The reaction was stopped with a mixture of methanol and perchloric acid (1 : 1) (50 *μ*L), centrifuged at 10000 rpm for 10 min, and 5°C, and 20 *μ*L of the supernatant injected into the HPLC. The metabolic profile was analyzed by HPLC-DAD, and the metabolites identified by mass spectrometry (ESI). Incubations were performed at least in duplicate.

### 2.2.3. Heme Peroxidases {#sec2.2.3}

0.5 mL reaction mixtures in 50 mM phosphate buffer (pH 7), containing lactoperoxidase (LPO) (0.18 *μ*M) or myeloperoxidase (MPO) (0.013 *μ*M), and MPTP (50, 250 *μ*M), MPDP^+^ (50, 250 *μ*M) or 2-methyl-1,2,3,4-tetrahydro-*β*-carboline (50, 250 *μ*M), and H~2~O~2~ (25 *μ*M) were incubated at 37°C, 40 min. Following the addition of HClO~4~ + methanol (1/1) (10% v/v of reaction volume), the tubes were centrifuged at 10000 rpm, 10 min, and 20 *μ*L of the supernatant injected into the HPLC. The metabolic profile was analyzed by HPLC-DAD, and the metabolites identified by mass spectrometry (ESI). Incubations were performed at least in duplicate.

### 2.2.4. RP-HPLC Chromatographic Analysis and Mass Spectrometry {#sec2.2.4}

The chromatographic analysis of the reaction products from enzyme incubations was performed by RP-HPLC with *uv-DAD*and fluorescence detection using an HPLC 1050 (Hewlett Packard) with a Diode Array Detector (DAD) and a 1046A-fluorescence detector \[[@B14], [@B15]\]. A 150 mm × 3.9 mm, 4 *μ*m, Nova-pak C18 column (Waters, Milford, MA, USA) was used for chromatographic separation. Chromatographic conditions were buffer A: 50 mM ammonium phosphate buffer (pH 3 for MAO and peroxidase assays or pH 5.5 for cytochrome P450 2D6) and buffer B: 20% of A in acetonitrile. Gradient was programmed from 0% (100% A) to 32% B at 8 min and 90% B at 15 min. The flow rate was 1 mL/min, the column temperature was 40°C, and the injection volume was 20 *μ*L. Absorbance detection was set at 355 nm for analysis of dehydrogenation products such as MPDP^+^ and 2-methyl-3,4-dihydro-*β*-carbolinium species (2-Me-DH*β*C^+^); 280 nm for analysis of MPP^+^; 254 nm for the analysis of 2-methyl-*β*-carbolinium cation; 280 nm for 2-methyltetrahydro-*β*-carboline (2-Me-TH*β*C) and its metabolites, 243 nm for PTP, and 254 nm for MPTP-OH. Calibration curves of absorbance versus concentration were constructed for each metabolite. Identification of metabolites was done by UV (DAD spectra) fluorescence and coelution with authentic standards. Confirmation of the identity was performed with HPLC-ESI-mass spectrometry \[[@B14], [@B15]\]. For that, separation was accomplished on a 2.1 × 150 mm Zorbax SB-C18 3.5 *μ*m column by using an HPLC-MSD Series 1100 (Hewlett Packard, Santa Clara, CA, USA) working under electrospray ionization positive-ion mode. Eluents: (A) formic acid (0.5%), (B) formic acid 0.5% in acetonitrile; 80% B in 30 min, flow: 0.25 mL/min, cone voltage: 70 V, and mass range: 50--600 amu.

3. Results and Discussion {#sec3}
=========================

The activation and inactivation of MPTP neurotoxin and 2-methyltetrahydro-*β*-carboline protoxin occur with the participation of key metabolic enzymes. This research studied and compared the metabolic profile generated from these substances by human monoamine oxidase, human cytochrome P450 2D6, and heme peroxidases ([Figure 2](#fig2){ref-type="fig"}). Human MAO enzymes (MAO-B) oxidized MPTP to give MPDP^+^ and MPP^+^ ([Figure 3(a)](#fig3){ref-type="fig"}). The main metabolite arising from MAO and MPTP was MPDP^+^, whereas MPP^+^ was produced through subsequent oxidation of MPDP^+^ ([Figure 4(a)](#fig4){ref-type="fig"}). As the pyridinium species are the directly acting neurotoxins in vivo, the oxidation by MAO is considered a key route for the bioactivation of MPTP ([Figure 2](#fig2){ref-type="fig"}) \[[@B8]\]. Indeed, inhibitors of MAO-B usually protect against this neurotoxin and can be useful as neuroprotectants \[[@B37], [@B40], [@B41], [@B54], [@B55]\]. Although human MAO-A was also able to oxidize MPTP in vitro as well, a number of studies have shown that MAO-B is the main isoform involved in this oxidation \[[@B54]--[@B57]\].

The neurotoxin MPTP was metabolized by the cytochrome P450 2D6 ([Figure 3(b)](#fig3){ref-type="fig"}). Two major metabolites were 4-(4′-hydroxyphenyl)-1-methyl-1,2,3,6-tetrahydropyridine (MPTP-OH) (aromatic hydroxylation) and 4-phenyl-1,2,3,6-tetrahydropyridine (PTP) (*N*-demethylation) ([Figure 4(b)](#fig4){ref-type="fig"}). In addition, the cytochrome P450 2D6 oxidized MPTP to give minor amounts of MPDP^+^ and MPP^+^, although this conversion was of lower efficiency compared with MAO ([Figure 4(c)](#fig4){ref-type="fig"}). On the other hand, two heme peroxidases (lactoperoxidase and myeloperoxidase) were unable to oxidize MPTP to pyridinium species in the presence of H~2~O~2~, indicating that MPTP was not a substrate of these kinds of oxidative enzymes. Interestingly, however, these peroxidases accelerated the oxidation of MPDP^+^ to MPP^+^ ([Figure 6(c)](#fig6){ref-type="fig"}). Although MPDP^+^ could be auto oxidized or disproportionated to give MPP^+^ \[[@B15], [@B58]\] as reported in [Figure 2](#fig2){ref-type="fig"}, peroxidases increased this oxidation when compared to controls. Then, activation of the MPDP^+^ to the directly acting neurotoxin MPP^+^ could be facilitated by heme peroxidases, and this might have further implications for the neurotoxicity of this and related substances ([Figure 2](#fig2){ref-type="fig"}).

In a search for analogies with MPTP, the naturally occurring *β*-carboline 2-methyltetrahydro-*β*-carboline was metabolized by the former enzymes ([Figure 2](#fig2){ref-type="fig"}). Human MAO enzymes (MAO-A or -B) did not afford any detectable metabolites of oxidation (i.e., *β*-carbolinium species). Therefore, MPTP and its *β*-carboline analogs behaved differently regarding the metabolism by MAO, suggesting that they differ in the activation pathway ([Figure 2](#fig2){ref-type="fig"}). Instead, the cytochrome P450 2D6 was able to metabolize the tetrahydro-*β*-carboline that was hydroxylated to two metabolites identified as 6-hydroxy-2-methyl-1,2,3,4-tetrahydro-*β*-carboline (6-OH-2-Me-TH*β*C) and 7-hydroxy-2-methyl-1,2,3,4-tetrahydro-*β*-carboline (7-OH-2-Me-TH*β*C) (Figures [5(a)](#fig5){ref-type="fig"} and [6(a)](#fig6){ref-type="fig"}). These polar metabolites could be considered detoxification metabolites, and, in that case, the cytochrome P450 2D6 can participate in an inactivation route of 2-methyltetrahydro-*β*-carboline, in a similar way to MPTP. On the other hand, 2-methyltetrahydro-*β*-carboline was oxidized in a reaction catalyzed by heme peroxidases in the presence of H~2~O~2~ ([Figure 5(b)](#fig5){ref-type="fig"}). This tetrahydro-*β*-carboline was oxidized by lactoperoxidase and myeloperoxidase to the corresponding 2-methyl-3,4-dihydro-*β*-carbolinium cation (2-Me-3,4-DH*β*C^+^) ([Figure 6(b)](#fig6){ref-type="fig"}) and traces detected of the fully aromatic *β*-carbolinium cation (2-methyl-*β*-carbolinium cation). The *β*-carbolinium species are neurotoxic substances \[[@B30], [@B33]\], and therefore this oxidation may represent a new route of activation of naturally occurring 2-methyltetrahydro-*β*-carbolines, which could be of significance for the toxicological fate of these substances ([Figure 2](#fig2){ref-type="fig"}). These results agree with the ability of tetrahydro-*β*-carbolines to be oxidized to dihydro- and aromatic *β*-carbolines \[[@B27], [@B59]\] and also with the participation of these substrates in a reduction of redox intermediates of peroxidases \[[@B53]\].

MPTP induces parkinsonism in humans and animal models, whereas the *β*-carbolines were postulated as possible toxins involved in neurodegeneration \[[@B20]\]. As seen in [Figure 2](#fig2){ref-type="fig"}, biochemical reactions leading to the activation/inactivation of these substances are critical for their toxicological outcome. A so-called "activation" to toxic pyridinium or *β*-carbolinium species is required for toxicity, whereas an "inactivation" may influence the fate of these protoxins in the body. Differences in the activation/inactivation balance and consequently in the response to these substances may arise from differences in the enzymes involved. The toxic response to MPTP largely varies between species \[[@B7], [@B10], [@B11]\], and this might result from differences in the expression and activity of metabolic enzymes \[[@B49], [@B50], [@B60], [@B61]\] producing a different ratio between toxic and inactive metabolites. The results reported here indicate substantial differences among the enzymes involved and profile ([Figure 2](#fig2){ref-type="fig"}). While MAO enzymes were responsible for the activation of MPTP to give toxic pyridinium species, heme peroxidases were activators of 2-methyltetrahydro-*β*-carbolines to pyridinium-like carbolinium toxins and MAO played no role. Although heme peroxidases were not involved in the MPTP activation, these enzymes catalyzed the oxidation step from MPDP^+^ to MPP^+^. Thus, heme peroxidases like myeloperoxidase may accelerate the flow from MPDP^+^ (i.e., produced by MAO) to MPP^+^. With these results in mind, peroxidases might play a role in the bioactivation of these or related protoxins, resulting in increased toxicity ([Figure 2](#fig2){ref-type="fig"}) \[[@B15]\]. In this regard, the potential involvement of peroxidases in neurodegeneration and Parkinson\'s disease has been already suggested \[[@B50]--[@B52], [@B62]\]. Myeloperoxidase occurs at sites of degenerative diseases and neuroinflammation and increases in Alzheimer\'s disease \[[@B48], [@B63]\], and its ablation mitigated PD produced by MPTP neurotoxin in animals \[[@B49]\].

MPTP and 2-methyltetrahydro-*β*-carbolines differed in the activation route to toxic metabolites (i.e., MAO versus heme peroxidase). However, both were metabolized by human cytochrome P450 2D6. This enzyme carried out the metabolism of MPTP by *N*-demethylation and aromatic hydroxylation and 2-methyltetrahydro-*β*-carboline by aromatic hydroxylation ([Figure 2](#fig2){ref-type="fig"}). The involvement of cytochrome P450 2D6 in detoxification is relevant, and some studies have reported an association between cytochrome P450 2D6 polymorphism and Parkinson\'s disease (PD) \[[@B44], [@B64]\]. This enzyme is lower in PD patients, which may reduce the ability of those patients to inactivate PD-causing neurotoxicity \[[@B64]\]. For example, exposure to pesticides increases the incidence of PD, and this risk was even higher in subjects with a poor metabolizer 2D6 genotype exposed to pesticides \[[@B3], [@B45]\]. In contrast to pyridinium species (i.e., MPDP^+^ and MPP^+^) produced by MAO, the MPTP-OH and PTP metabolites arising from cytochrome P450 2D6 are thought to be devoid of neurotoxicity \[[@B12], [@B65]\]. Therefore, cytochrome P450 2D6 competes with MAO enzymes in favour of an inactivation route of the MPTP neurotoxin \[[@B14]\]. Results in [Figure 4](#fig4){ref-type="fig"} also showed that P450 2D6 slightly activated MPTP to the pyridinium species, MPDP^+^ and MPP^+^. Recently, a mitochondrial cytochrome P450 2D6 was reported that was able to carry out the activation of MPTP to pyridinium species (MPDP^+^ and MPP^+^) suggesting a role for this enzyme in the activation process and toxicity \[[@B17]\]; however, this conversion appeared to be of lower significance compared with MAO \[[@B14]\].

*β*-Carbolines abound in plants and foods and appear in biological tissues including the brain \[[@B25], [@B27], [@B66], [@B67]\]. They exert psychopharmacological and behavioural effects \[[@B23]--[@B27], [@B54], [@B66], [@B68]\]. An involvement of tetrahydro-*β*-carbolines (and/or *β*-carbolines) as proneurotoxins is based on the fact that these compounds are *N*-methylated to *N*(2)-methyltetrahydro-*β*-carbolines which can be subsequently oxidized to *N*(2)-methyl-*β*-carbolinium species \[[@B20], [@B21], [@B29], [@B33], [@B69]\]. *N*-Methylation of tetrahydro-*β*-carbolines (TH*β*C) is catalyzed by brain *N*-methyltransferases \[[@B69]\], and 2-methyltetrahydro-*β*-carboline has been detected in rat brain \[[@B70]\]. However, this sequence lacks a step of activation to *β*-carbolinium species. 2-Methyltetrahydro-*β*-carboline is not neurotoxic \[[@B65]\] but it could be oxidized (activated) to toxic *β*-carbolinium cation (*β*C^+^) by heme peroxidases/H~2~O~2~ (lactoperoxidase and myeloperoxidase) (Figures [2](#fig2){ref-type="fig"} and [6](#fig6){ref-type="fig"}). *β*-Carbolinium species resemble MPP^+^ in many of their toxicological features. *N*-Methyl-*β*-carbolinium cation (2-Me-*β*C^+^) and *N*,*N*-dimethyl-*β*-carbolinium cation (2,9-diMe-*β*C^+^) are neurotoxins producing irreversible striatal lesions \[[@B31], [@B71]\]. These carbolinium species (2-Me-*β*C^+^ and 2,9-diMe-*β*C^+^) were found in normal and parkinsonian brains \[[@B34]--[@B36]\] and appeared in higher proportion in the brain and cerebrospinal fluid of PD patients \[[@B34], [@B35]\]. As the cytochrome P450 2D6 contributes to the metabolism of tetrahydro-*β*-carbolines to hydroxylated metabolites \[[@B14], [@B43]\], this route could be competitive against the oxidation by peroxidases and the *N*-methylation by *N*-methyltransferases \[[@B14], [@B15], [@B21]\]. The biotransformation of *β*-carbolines by cytochrome P450 2D6 may influence the outcome of these substances as eventual protoxins and generate differences depending on enzyme polymorphism.

In summary, these results indicate that activation/inactivation of MPTP and 2-methyltetrahydro-*β*-carboline protoxins depends on three key oxidative enzymes that are crucial for toxicity and detoxification. MPTP relays on MAO enzymes for activation (toxicity) with a possible role for heme peroxidases. However, it relays on cytochrome P450 2D6 for inactivation. In contrast, 2-methyltetrahydro-*β*-carbolines depend on heme peroxidases for activation to toxic carbolinium species and cytochrome P450 2D6 for detoxification with no role played by MAO enzymes. It can be concluded that the degree of toxicity caused by those protoxins may result from a balance between the rate of activation to toxic products (i.e., *N*-methylpyridinium---MPP^+^ and MPDP^+^---and *N*-methyl-*β*-carbolinium---*β*C^+^---) and the rate of inactivation (detoxification) (i.e., *N*-demethylation, aromatic hydroxylation). As the enzymes involvement may vary in expression and activity between persons, major differences in the toxicological outcome of these protoxins are foreseen.
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![Activation of MPTP to the directly acting neurotoxin MPP^+^, which is uptaken by dopaminergic cells via DAT (dopamine active transporter) and produces neurotoxicity and cell death. *β*-Carbolinium cations (*β*C^+^) are toxic analogs of MPP^+^ that may arise from 2-methyl-1,2,3,4-tetrahydro-*β*-carbolines.](BMRI2013-248608.001){#fig1}

![Proposed activation and inactivation routes and metabolites from MPTP and 2-methyl-1,2,3,4-tetrahydro-*β*-carboline (2-Me-TH*β*C) protoxins resulting from human monoamine oxidase (MAO), heme peroxidases (lactoperoxidase and myeloperoxidase), and human cytochrome P450 2D6.](BMRI2013-248608.002){#fig2}

![HPLC chromatograms of MPTP oxidized by human MAO-B (a) and MPTP oxidized by human cytochrome P450 2D6 (b). Enzyme assays and chromatographic conditions were as indicated in experimental section.](BMRI2013-248608.003){#fig3}

![Metabolites and rates produced from MPTP neurotoxin (50 and 250 *μ*M) by human MAO-B (0.05 mg/mL protein) (a) and human cytochrome P450 2D6 (b) and (c). Enzyme assays were as indicated in experimental section.](BMRI2013-248608.004){#fig4}

![HPLC chromatograms of metabolites from 2-methyl-1,2,3,4-tetrahydro-*β*-carboline incubated with cytochrome P450 2D6 (a) and myeloperoxidase (b). Enzyme assays and chromatographic conditions were as indicated in experimental section.](BMRI2013-248608.005){#fig5}

![Metabolites and rates produced from 2-methyl-1,2,3,4-tetrahydro-*β*-carboline (2-Me-TH*β*C) by cytochrome P450 2D6 (a) and lactoperoxidase (LPO) and myeloperoxidase (MPO) (b). (c) Corresponds to the formation of MPP^+^ from MPDP^+^ as catalyzed by peroxidases LPO and MPO (the corresponding controls with H~2~O~2~ and no enzyme are subtracted). Enzyme assays were as indicated in experimental section.](BMRI2013-248608.006){#fig6}
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